The in vitro activity of tigecycline was evaluated against 4913 baseline pathogens isolated from 1986 patients enrolled in 4 pivotal phase 3 clinical trials. The trials, which were conducted in 38 countries worldwide, involved patients with complicated skin and skin-structure infections or complicated intra-abdominal infections. Tigecycline was active against the most prevalent pathogens for each infection type, including grampositive and gram-negative strains of both aerobic and anaerobic bacteria (MICs, р2 mg/mL for most pathogens). The spectrum of activity of tigecycline included important pathogens, such as Staphylococcus aureus (including methicillin-resistant S. aureus), Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, and Bacteroides fragilis. A few genera, such as Pseudomonas aeruginosa and members of the tribe Proteeae, were generally less susceptible to tigecycline than were other gram-negative pathogens. The susceptibility of the pathogens to tigecycline was similar for isolates obtained from patients enrolled in the studies of complicated skin and skin-structure infection or of complicated intra-abdominal infection. For most pathogens, the susceptibility to tigecycline was similar across all geographic regions. The excellent expanded broad-spectrum activity of tigecycline demonstrated in vitro against clinical isolates confirmed its potential utility for pathogens associated with complicated skin and skin-structure infections or complicated intra-abdominal infections.
Tigecycline, the 9-t-butylglycylamido derivative of minocycline, is the first in the class of glycylcycline antibiotics and was developed by Wyeth in response to the worldwide threat of emerging resistance to antibiotics [1] . Tigecycline acts by inhibition of protein translation in bacteria, by binding to the 30S ribosomal subunit, and by blocking entry of amino-acyl tRNA molecules into the A site of the ribosome [2] . This action prevents incorporation of amino acid residues into elongating peptide chains. Unlike the classical tetracyclines, tigecycline is not affected by any of the known determinants addition, the susceptibility of these isolates to tigecycline was compared by geographic location.
MATERIALS AND METHODS
Double-blind clinical trials comparing the safety and efficacy of tigecycline with that of an active comparator for the treatment of cSSSI or cIAI were conducted from 2002 to 2004 [8] [9] [10] [11] . Isolates from patients enrolled in the tigecycline and comparator treatment groups were used in this analysis. Specimens obtained from patients were processed, and bacterial pathogens were cultured by each site laboratory according to local practices. Individual investigators sent all bacterial isolates to a central laboratory for identification and susceptibility tests, which were performed in real time for the duration of the clinical trials. For aerobic organisms, susceptibility to tigecycline and tetracycline was determined by broth microdilution with fresh media by use of reference methods recommended by the Clinical Laboratory Standards Institute (formerly National Committee for Clinical Laboratory Standards) [12] . MICs were determined in Mueller-Hinton II broth for most organisms. For determinations of streptococcal MICs, Mueller-Hinton II broth containing 5% lysed horse blood was used. MICs of other antibiotics were determined with custom-prepared dehydrated microdilution panels (Trek Diagnostics), according to the manufacturer's instructions. Reference antibiotics included the comparative agents for both the SSSI and IAI clinical trials, as well as antibiotics of different drug classes chosen to generate information with regard to general susceptibility patterns of the organisms isolated during the trials. For anaerobic organisms, MICs were determined by standard agar dilution methodology [13] . Methicillin resistance of staphylococci was determined by MIC tests for oxacillin supplemented with 2% NaCl and interpreted according to Clinical Laboratory Standards Institute interpretive criteria [12, 14] . In this study, only baseline pathogens were included in the analysis of susceptibility to tigecycline and comparative agents.
RESULTS
A total of 1480 baseline pathogens were obtained from 742 patients in 2 clinical trials of patients with cSSSI, and 3433 baseline isolates were obtained from 1244 patients in the 2 studies of patients with cIAI. The most prevalent pathogens isolated are shown in table 1. The distribution of pathogens was typical for each infection type and was similar to results from previous studies [15] [16] [17] . Among patients with cSSSI, the most prevalent pathogens isolated were Staphylococcus aureus (both methicillin-resistant and methicillin-susceptible), Escherichia coli, and Streptococcus pyogenes, whereas E. coli, Bacteroides fragilis group (including B. fragilis), and Streptococcus anginosus group were predominant among patients with cIAI. The susceptibility to tigecycline and comparative antibiotics of the pathogens isolated in the clinical trials is shown in tables 2, 3, and 4. Tigecycline was active against strains of Staphylococcus species, regardless of the susceptibility to methicillin or oxacillin (table 2) . All strains of Staphylococcus species that were tested were inhibited by tigecycline at a concentration of р2 mg/mL. For S. aureus, the tigecycline MIC 90 for both methicillinsusceptible and methicillin-resistant strains was 0.25 mg/mL in both the cSSSI and cIAI studies. Although most of the methicillin-susceptible S. aureus were susceptible to minocycline and levofloxacin, the levofloxacin MIC 90 of levofloxacin (116 mg/ mL) was above the resistance break point for methicillin-resistant S. aureus isolates from both types of clinical infection. Tigecycline and minocycline MICs were directly compared on a strain-by-strain basis for methicillin-resistant S. aureus ( figure  1A ). By this analysis, 11 minocycline-resistant methicillin-resistant S. aureus were identified that required low tigecycline MICs (р0.5 mg/mL). Similarly, the MIC 90 values for tigecycline were 0.25 and 0.5 mg/mL for methicillin-susceptible and methicillin-resistant strains of Staphylococcus epidermidis, respectively. Tigecycline was also active against Staphylococcus haemolyticus, with an MIC 90 of 1 mg/mL for isolates from cSSSI and 0.5 mg/mL for isolates from cIAI studies. The in vitro activity of tigecycline was determined against clinical isolates of Enterococcus species (table 2). All isolates of enterococci were inhibited by р0.5 mg/mL tigecycline. For Enterococcus faecalis, tigecycline was equally active against isolates obtained from patients in both the cSSSI and cIAI studies (MIC 90 , 0.25 mg/mL). In contrast, levofloxacin, tetracycline, and minocycline MIC 90 values were above the susceptibility break point for E. faecalis isolates obtained from patients in both cSSSI and cIAI studies. A direct comparison of tigecycline with minocycline revealed that all of the E. faecalis strains that were resistant to minocycline were inhibited by р0.25 mg/mL tigecycline (figure 1B). Enterococcus faecium had a similar response when tested with tigecycline, with an MIC 90 of 0.12 mg/mL for isolates from both the cSSSI and cIAI studies. Interestingly, compared with isolates obtained in the cSSSI studies, more of the E. faecium isolated in the cIAI trials were resistant to minocycline (MIC 90 , 0.25 vs. 16 mg/mL in cSSSI and cIAI studies) and tetracycline (MIC 90 , 0.5 vs. 164 mg/mL in cSSSI and cIAI studies). In addition, tigecycline was active against Enterococcus avium (MIC 90 , 0.12 mg/mL) and Enterococcus hirae (MIC 90 , 0.06 mg/mL) isolated from patients in the cIAI studies.
Tigecycline had good activity against the b-hemolytic streptococci (table 2). All strains of Streptococcus agalactiae, S. pyogenes, and Streptococcus dysgalactiae were inhibited by р0.25 mg/mL tigecycline. This concentration of tigecycline was also the MIC 90 for S. agalactiae and S. dysgalactiae in the cSSSI studies, whereas the tigecycline MIC 90 for S. pyogenes was 0.12 mg/mL. For all 3 species of b-hemolytic streptococci, the tetracycline and minocycline MIC 90 values were above the resistance break point. In addition, tigecycline inhibited a-hemolytic streptococci, with an MIC of р1 mg/mL. For S. anginosus, the tigecycline MIC 90 was 0.12 mg/mL for isolates obtained from both cSSSI and cIAI studies.
Tigecycline has also demonstrated good activity against gram-negative bacterial pathogens, especially the Enterobacteriaceae (table 3) . For Citrobacter freundii, tigecycline inhibited all of the strains tested, with an MIC of р2 mg/mL, and the MIC 90 was 1 mg/mL for isolates from the cIAI studies. In contrast, the minocycline (16 mg/mL), tetracycline (164 mg/mL), aztreonam (32 mg/mL), and ceftazidime (32 mg/mL) MIC 90 values were above the respective resistance break points. Tigecycline was also active against strains of Citrobacter braakii (MIC 90 , 0.5 mg/mL for isolates from cIAI studies). For Enterobacter species, the activity of tigecycline was tested against 82 strains of Enterobacter cloacae, with MIC 90 values of 1 mg/mL for isolates from both infection types. The range of tetracycline, aztreonam, ceftazidime, and piperacillin-tazobactam MICs were similar for isolates from cSSSI and cIAI studies; however, the MIC 90 values for these antibiotics were significantly higher for isolates from the cIAI studies.
All E. coli isolates were inhibited by р2 mg/mL tigecycline, including strains that were resistant to minocycline and tetracycline ( figure 2A) . Similarly, tigecycline was active against Klebsiella pneumoniae isolates, with an MIC 90 of 1 mg/mL for strains from both the cSSSI and cIAI studies. These strains included some that were resistant to the expanded-spectrum b-lactam antibiotics ceftazidime and aztreonam (MIC range, р0.12 to 164 mg/mL for both). A few strains of K. pneumoniae were noted that required higher tigecycline MICs (4 mg/mL). The mechanism for the decreased susceptibility to tigecycline in these strains has been attributed to the overexpression of the transcriptional activator ramA [18] . In addition to K. pneumoniae, tigecycline is also active against Klebsiella oxytoca. All 70 strains of K. oxytoca tested were inhibited by 0.5 mg/mL tigecycline, which was also the MIC 90 for isolates from both infection types. A wide range of activity against 22 clinical isolates of Serratia marcescens (0.5-8 mg/mL) was observed. However, the majority of the strains had lower MICs, as reflected by the MIC 50 values of 1 and 2 mg/mL for isolates from cSSSI and cIAI studies, respectively. The activity of tigecycline has also been tested against the Proteeae (table 3) . Although a number of genera display a wide range of MICs, there was a trend for tigecycline MICs to be higher for Proteeae than for other members of the Enterobacteriaceae. The mechanism for this has been attributed to the overexpression of the AcrAB efflux pump in these organisms [19, 20] . For the 85 strains of Proteus mirabilis, the tigecycline MIC 90 was 4 mg/mL for isolates from both cSSSI and cIAI studies. In addition, the minocycline MIC 90 values were 32 and 64 mg/mL, and the tetracycline MIC 90 values were 164 and 64 mg/mL for isolates from the cSSSI and cIAI studies, respectively. For strains from the cIAI studies, the tigecycline MIC 90 was 2 mg/mL for both Morganella morganii and Proteus vulgaris.
A number of gram-negative pathogens from families other than Enterobacteriaceae were also isolated during the course of the clinical trials (table 3) . Tigecycline demonstrated good activity against 32 strains of Acinetobacter baumannii: the MIC 90 values for strains from cSSSI and cIAI studies were 1 and 2 mg/mL, respectively. A direct comparison of tigecycline and minocycline MICs revealed that some strains of Acinetobacter species required lower minocycline MICs than tigecycline MICs (figure 2B). However, there was no overall trend, and these values appear to be scattered around the line of equivalence. In addition, there was no strong clustering of strains indicating any specific resistance mechanism for either tigecycline or minocycline. The tetracycline, aztreonam, ceftazidime, and piperacillin-tazobactam MIC 90 values were above the resistance break point for strains from both infection studies. Tigecycline has less activity against Pseudomonas aeruginosa than it does against some of the other non-Enterobacteriaceae. The majority of the strains required 16 mg/mL (MIC 50 ) or 32 mg/mL (MIC 90 ) for inhibition. Investigations into the mechanism for decreased susceptibility of P. aeruginosa to tigecycline identified the MexXY-OprM efflux system [21] . In addition, tigecycline was active against 10 strains of Comamonas testosterone isolated from the cIAI trials (MIC 90 , 0.12 mg/mL). Tigecycline was also shown to have good activity against anaerobic pathogens. All gram-positive anaerobic bacteria isolated from the clinical trials were inhibited by р2 mg/mL tigecycline (table 4) . Strains of Clostridium innocuum and Clostridium perfringens were inhibited by tigecycline at MIC 90 values of р0.06 and 1 mg/mL, respectively. Some of the strains of C. perfringens were noted to be resistant to levofloxacin (MIC range, 0.12 to 116 mg/mL) and vancomycin (MIC range, 0.25-32 mg/mL). Tigecycline was also active against Eubacterium lentum, Peptostreptococcus micros, and Propionibacterium acnes, with MIC 90 values of 0.5, р0.06, and 0.12 mg/mL, respectively.
For members of the B. fragilis group, there was a wide range of tigecycline MICs for most species (range, 0.06-16 mg/mL). However, the MIC 50 for all species of Bacteroides was р2 mg/ mL. In addition, the tigecycline MIC 90 was 1 or 2 mg/mL for Bacteroides distasonis, Bacteroides thetaiotaomicron, Bacteroides uniformis, and Bacteroides vulgatus. For B. fragilis, the MIC 90 for isolates from the cSSSI studies was 0.25 mg/mL, compared with 4 mg/mL for isolates from the cIAI studies. An explanation may be that the number of strains isolated in the cIAI trials was 10 times greater than the number isolated from the cSSSI trials. The larger sample of isolates from cIAI trials probably ) and Enterococcus faecalis (B; ). The diagonal line represents strains that required equivalent MICs. Strains above the diagonal n p 143 n p 168 were more susceptible to minocycline and strains below were more susceptible to tigecycline.
provided a greater likelihood of a wider range of MICs. In addition, tigecycline showed good activity against Fusobacterium nucleatum (MIC 90 , 0.12 mg/mL) and Veillonella species (MIC 90 , 0.5 mg/mL).
The susceptibility data for tigecycline with the most prevalent pathogens from the phase 3 clinical trials was also analyzed for regional variability (table 5) . For all of the gram-positive pathogens (S. aureus, S. pyogenes, E. faecalis, and the S. anginosus group), the MIC 50 and MIC 90 values were nearly identical, varying by only 1 dilution between the pathogens isolated from patients in various regions of the world. Likewise, the tigecycline susceptibilities for E. coli isolated from cIAI studies were identical for all regions (MIC 50 , 0.25 mg/mL; MIC 90 , 0.5 mg/mL). In addition, there was no difference in the susceptibility of K. pneumoniae isolated from the various regions. More variability in susceptibility was seen among the isolates of Bacteroides species. For example, the MIC 90 values for B. fragilis ranged from 1 mg/mL (western Europe) to 8 mg/mL (South Africa). For the B. fragilis group, not B. fragilis, the MIC 90 values ranged from 2 mg/mL (western and eastern Europe and the Asia-Pacific region) to 16 mg/mL (Latin America) (regions are defined in table 5).
DISCUSSION
Tigecycline is an antibacterial agent with an expanded broad spectrum of activity against most pathogenic bacteria. It was specifically designed to have activity against resistant organisms harboring either of the 2 classic tetracycline resistance mechanisms (i.e., ribosomal protection or specific efflux pumps) [1, ). The diagonal line represents strains that required equivalent MICs. Strains above the n p 32 diagonal were more susceptible to minocycline and strains below were more susceptible to tigecycline. 3]. In preclinical studies, tigecycline was shown to have activity against a broad range of gram-positive pathogens (e.g., methicillin-resistant S. aureus, vancomycin-resistant E. faecalis and E. faecium, and penicillin-resistant S. pneumoniae), gram-negative pathogens (e.g., extended-spectrum b-lactamase-producing E. coli and K. pneumoniae), anaerobic bacteria (e.g., the B. fragilis group), and "atypical" bacteria (e.g., Mycoplasma species, Chlamydia species, and rapidly growing Mycobacterium species) [4] [5] [6] [7] [22] [23] [24] .
The results of the present study demonstrate that the susceptibility to tigecycline of the clinical isolates obtained in phase 3 clinical trials was similar to that seen in the preclinical studies. For example, the tigecycline MIC 90 for methicillin-resistant S. aureus was 0.25 mg/mL for isolates from a multilaboratory preclinical study and the cSSSI and cIAI clinical trials [4, [8] [9] [10] [11] . Similarly, the MIC 90 for E. coli was 0.5 mg/mL for both preclinical and clinical isolates, and the MIC 90 for B. fragilis was 4 mg/mL for both subsets of isolates.
The isolates from the clinical trials were obtained from patients enrolled in 38 countries in North America, Latin America, western Europe, eastern Europe, India, the Asia-Pacific region, South Africa, and Australia. In general, no regional differences were noted in the susceptibility to tigecycline of isolates from the various regions. However, these analyses were performed for relatively few isolates for each region. Therefore, more isolates from each region should be tested to determine whether there are trend differences in the tigecycline MICs in certain regions. These results are in agreement with results obtained previously from a number of large in vitro susceptibility studies that included isolates from North America, Latin America, Europe, the Middle East, and Asia [24] [25] [26] [27] [28] . All of these studies reported good activity against a wide variety of pathogens, most of which were inhibited by р2 mg/mL tigecycline. The impressive in vitro spectrum of tigecycline suggests that this antibiotic might be considered for use as monotherapy in the treatment of diverse infections. Tigecycline has been shown to be safe and effective in double-blind, multicenter clinical trials. In 2 trials of cSSSI, conducted in North America, Latin America, India, and the Asia-Pacific region [10] and in Europe, South Africa, and Australia [8] , investigators reported excellent responses in patients treated with tigecycline. Similarly favorable outcomes were noted for patients enrolled in 2 studies of cIAI by investigators in the 2 regional trials [9, 11] . In summary, the in vitro activity of tigecycline against a broad spectrum of gram-positive and gram-negative aerobic and anaerobic pathogens isolated from patients enrolled in phase 3 clinical trials conducted worldwide showed an excellent susceptibility profile and suggests its utility in the treatment of patients with cSSSI and cIAI.
